3[1]Wood D,De Backer G,Faergeman O,et al.Task Force Reporta:Prevention of coronary heart disease in clinical practice.Recommendation of the second joint Tasl fpree of European and other societies on Coronmy Prevention[J].Eur Heart J,1998,19:1434-1503.
4[4]Heart protection study collaborative croup.MRC/BHF Heart protection study of cholestroe lowering with sim vastatin in.20536high-rist individuals:a randomized placebo-controlled trial[J].Lancet,2002,360:7-22.
5Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes:a randomised placebo-controlled trial[J]. Lancet ,2003,361:2005-2016.
6Sever PS,Dahlof B, Poulter NR,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) : a multicenter randomized controlled trial[J]. Lancet,2003,361:1149-1158.
7Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention[J]. Circulation ,2003,107:363-369.
8Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events[J]. N Engl J Med,2002,347:1557-1565.
9Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14,719 initially healthy Americau women[J]. Circulation,2003,107:391-397.
10Ridker PM, Rifai N, Pfeffer M, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein[ J]. Circulation, 1999,100:230-235.
